Skip to content

Author

Jiu-Wei Cui

We have 8 of 628 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Review Oct 2026

Izalontamab brengitecan for HR+/HER2- breast cancer in China (PANKU-Breast01): a randomised, phase 3 trial.

BACKGROUND Patients with heavily pretreated hormone receptor-positive and human epidermal growth factor receptor 2-negative (HR+/HER2-) breast cancer have few treatment options. Izalontamab brengitecan (iza-bren) is a first-in-class, epidermal growth factor receptor and HER3 bispecific antibody-drug conjugate that cont...

B. Lan, Ye-Hui Shi, Xi-Ying Shao et al. · 0 citations
Review Open access Oct 2026

Trastuzumab Rezetecan in ERBB2-Low Advanced Breast Cancer: The HORIZON-Breast06 Randomized Clinical Trial.

Importance Trastuzumab rezetecan (SHR-A1811) has demonstrated encouraging antitumor activity in a global phase 1 trial involving heavily pretreated patients with erythroblastic oncogene B (ERBB2)-low metastatic breast cancer. Objective To compare trastuzumab rezetecan vs physician's choice of chemotherapy in patients...

Y. Fan, Yun-Jiang Liu, Yong-Sheng Wang et al. · 1 citation
Review Open access Sep 2026

The oral–lung axis in lung cancer: microbial translocation, immune reprogramming, and clinical implications

The oral–lung axis describes microbial and inflammatory exchange between the oral cavity and the lower respiratory tract. Its relevance to lung cancer is supported by the detection of oral-associated taxa in lower-airway samples, epidemiological links between periodontal disease and lung cancer risk, and experimental e...

Xiang-Liang Liu, Guan-Ran Ding, Jin Lu et al. · 0 citations
Review Open access Aug 2026

Circulating tumor DNA in lung cancer immunotherapy: prognostic marker today, predictive tool tomorrow?

Circulating tumor DNA currently functions mainly as a prognostic and response-associated biomarker in lung cancer immunotherapy, while its predictive, decision-defining role remains an important but investigational objective.

Yan Li, Guan-Yu Lu, Wei Song et al. · 0 citations
Review Jul 2026

Pulmonary nodule prediction in the multi-omics era: integrating radiomics, AI, liquid biopsy, and airway classifiers.

The need for prospective validation and multidisciplinary collaboration to translate advances in radiomics, AI, liquid biopsy, airway classifiers, and multi-omics integration into clinically useful pathways that improve early lung cancer detection, reduce unnecessary interventions, and enhance patient outcomes is highl...

Yan Li, Guan-Yu Lu, Xiang-Liang Liu et al. · 0 citations
Review Aug 2026

The ER stress-autophagy axis in cancer-induced muscle wasting: Unveiling the IRE1α/XBP1 pathway as a therapeutic target.

This review examines how tumor-derived signals activate IRE1α/XBP1 to upregulate both the autophagy-lysosome pathway (ALP) and ubiquitin-proteasome system (UPS); its crosstalk with inflammatory and metabolic networks; and the therapeutic potential of IRE1α inhibitors, XBP1-directed strategies, and nutritional approache...

Guan-Ran Ding, Wang Yang, Yi-Xin Zhao et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.